Abbvie’s Botox launches for wide jaw appearance in China
by
Contributor since / Followers
Contributor since / Followers
1 week ago
Enes Evren/E+ via Getty Images
- AbbVie (NYSE:ABBV) subsidiary Allergan Cosmetics has launched Botox (onabotulinumtoxinA) in China to treat masseter muscle prominence, a condition that can result in a wide and square lower face shape.
- Botox is the first neurotoxin approved in the country for this indication.
- A company news release stated that masseter muscle prominence is a top appearance concern for many Chinese. Botox is dosed every six months for the condition.
- An Allergan executive said that the indication is a “key focus for our global R&D pipeline.”
- Approval was supported by a phase 3 trial in which patients taking Botox saw a 5.2mm greater average reduction of facial width compared to those given placebo with results lasting around six to nine months after treatment.